Your browser doesn't support javascript.
loading
Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
Ollivier-Hourmand, Isabelle; Lebedel, Louise; Alabau, Berta Bartroli; Goria, Odile; Bureau, Christophe; Dumortier, Jérome; Heurgué, Alexandra; Silvain, Christine; De-Ledinghen, Victor; Rautou, Pierre-Emmanuel; Payancé, Audrey; Ballester, Teresa García; Alvarado-Tapias, Edilmar; Hernández-Gea, Virginia; Valla, Dominique; Zekrini, Kamal; Nga Nguyen, Thi Thu; Dao, Thong; Garcia Pagan, Juan Carlos; Morello, Rémy; Plessier, Aurélie.
Afiliação
  • Ollivier-Hourmand I; Hepatology unit, University Hospital Côte de Nacre, Caen, France.
  • Lebedel L; Hepatology unit, University Hospital Côte de Nacre, Caen, France. Electronic address: lebedel-l@chu-caen.fr.
  • Alabau BB; Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of t
  • Goria O; Hepatology unit, University Hospital Charles-Nicolle, Rouen, France.
  • Bureau C; Hepatology unit, University Hospital Purpan, Toulouse, France.
  • Dumortier J; Hepatology unit, University Hospital Edouard Herriot, Lyon, France.
  • Heurgué A; Hepatology unit, University Hospital Robert Debré, Reims, France.
  • Silvain C; Hepatology unit, University Hospital, Poitiers, France.
  • De-Ledinghen V; Hepatology unit, University Hospital Haut Levêque & INSERM U1312; Université de Bordeaux, Bordeaux, France.
  • Rautou PE; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
  • Payancé A; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
  • Ballester TG; Cardiology Department, Hospital Clínico Universitario, Universitat de Valencia, INCLIVA, Valencia, Spain.
  • Alvarado-Tapias E; Centro De Investigación Biomédica Red De Enfermedades Hepáticas y Digestivas (CIBERehd)), Spain; Servei De Patologia Digestiva, Hospital De La Santa Creu I Sant Pau, Spain.
  • Hernández-Gea V; Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of t
  • Valla D; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
  • Zekrini K; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
  • Nga Nguyen TT; Hepatology unit, University Hospital Côte de Nacre, Caen, France.
  • Dao T; Hepatology unit, University Hospital Côte de Nacre, Caen, France.
  • Garcia Pagan JC; Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of t
  • Morello R; Statistics Department, Hospital Côte de Nacre, Caen, France.
  • Plessier A; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
J Hepatol ; 81(3): 451-460, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38679069
ABSTRACT
BACKGROUND &

AIMS:

One-third of non-cirrhotic portal vein thrombosis (NCPVT) cases are associated with local factors. The risk of rethrombosis after anticoagulation withdrawal is unknown. We aimed to determine factors associated with new splanchnic or extrasplanchnic thrombotic events in this setting.

METHODS:

We performed a retrospective study including cases of recent NCPVT associated with local factors. High- and low-risk prothrombotic factors, prespecified according to RIPORT study criteria, were assessed. Univariate and multivariate Cox models assessed the influence of different variables on the occurrence of new thrombotic events.

RESULTS:

At baseline, 83/154 (53.9%) patients had at least one prothrombotic factor including 50 (32.5%) with a high-risk and 33 (21.4%) with a low-risk prothrombotic factor. Oestrogen-containing contraception was discontinued in all patients. During follow-up, 63/140 (45%) patients had at least one prothrombotic factor, including 47 (33.6%) with a high-risk and 16 (11.4%) with a low-risk prothrombotic factor. Seventeen new thrombotic events occurred after a median follow-up of 52 (IQR 14-62) (min-max 3.0-69.0) months. New thromboses were associated with high-risk factors (hazard ratio [HR] 3.817, 95% CI 1.303-11.180, p = 0.015), but were inversely related to recanalization (HR 0.222, 95% CI 0.078-0.635, p = 0.005) and anticoagulation (HR 0.976, 95% CI 0.956-0.995, p = 0.016). When a high-risk factor was present a new thrombotic event occurred in 7.4%, 14.6%, 14.6% and 28.8% of patients at 1, 3, 5 and 7 years under anticoagulants, respectively, compared to 21.2%, 21.2%, 58% and 58% without anticoagulants, respectively.

CONCLUSIONS:

In cases of recent NCPVT associated with local factors, high-risk factors for thrombosis are associated with new thrombotic events. Permanent anticoagulation appears beneficial in this high-risk situation. IMPACT AND IMPLICATIONS In non-cirrhotic portal vein thrombosis (NCPVT) associated with local factors, systematic screening for prothrombotic factors is recommended, but the prevalence of the latter is not clearly established, and the risk of recurrent intra or extrasplanchnic thromboembolism is poorly described. Thus, interest in permanent anticoagulation remains. NCPVT associated with local factors is a matter of concern for hepatologists, gastroenterologists and digestive surgeons. Due to a lack of knowledge, practices are heterogeneous. Our findings highlight that systematic screening for prothrombotic factors in NCPVT is needed even when associated with local factors, as it may justify long-term anticoagulation for the prevention of new intra or extrasplanchnic thrombotic events in at least one-third of cases. The interest in long-term anticoagulation should be investigated prospectively in the absence of high-risk prothrombotic factors. CLINICAL TRIAL NUMBER NCT0536064.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Veia Porta / Recidiva / Trombose Venosa Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hepatol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Veia Porta / Recidiva / Trombose Venosa Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hepatol Ano de publicação: 2024 Tipo de documento: Article